Pfizer Halts Sutent's Phase III in Hepatocellular Carcinoma

Failure is the second in two months for Sutent, which is a lynchpin of Pfizer's oncology strategy.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet